
    
      Primary Purpose - other: Protocol designed to assess the safety, tolerability,
      immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-986089 in healthy
      subjects

      Enrollment: Single ascending dose panels: 48 subjects, Multiple ascending dose panels: 96

      Minimum age: 18 years (Elderly MAD Panel 65 years of age) Maximum age: 55 years (Elderly MAD
      Panel 70 years of age)
    
  